albuterol has been researched along with Disease Models, Animal in 99 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have compared the prophylactic efficacies of quercetin and salbutamol in preventing pulmonary surfactants oxidation under hypoxia." | 8.02 | Hypoxia-mediated alterations in pulmonary surfactant protein expressions: Beneficial effects of quercetin prophylaxis. ( Kumar, B; Sagi, SSK; Tripathi, A, 2021) |
| "Male SD rats supplemented orally with quercetin (50 mg/Kg BW), and salbutamol (2 mg/Kg BW) were exposed to hypobaric hypoxia at 7620 m for 6 h." | 7.96 | Efficacy of Quercetin as a potent sensitizer of β2-AR in combating the impairment of fluid clearance in lungs of rats under hypoxia. ( Kaur, P; Kumar, B; Kumar, M; Sagi, SSK; Tripathi, A, 2020) |
| "This study characterized a novel inhaled Btk inhibitor RN983 in vitro and in ovalbumin allergic mouse models of the early (EAR) and late (LAR) asthmatic response." | 7.83 | Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma. ( Bauer, CM; Burns, L; Harris, P; Laine, D; Peng, R; Phillips, JE; Renteria, L; Stevenson, CS, 2016) |
| " albuterol, are used for quick reversal of bronchoconstriction in asthmatics." | 7.77 | Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma. ( Aimi, S; Barone, LM; Bates, JH; Irvin, CG; Lundblad, LK; Poynter, ME; Riesenfeld, EP; Rinaldi, LM; Wu, M, 2011) |
| "Effects of quercetin inhalation on immediate (IAR), late-phase (LAR) and late late-phase (LLAR) asthmatic responses by exposure to aerosolized-ovalbumin (AOA) (2w/v% in saline, inhalation for 3 min) were studied in conscious guinea-pigs sensitized with AOA." | 7.74 | Quercetin inhalation inhibits the asthmatic responses by exposure to aerosolized-ovalbumin in conscious guinea-pigs. ( Choi, HH; Kim, CJ; Lee, JY; Moon, H; Moon, HJ; Sim, SS, 2008) |
| "(R)- and (S)-Enantiomers of albuterol likely exert differential effects in patients with asthma." | 7.73 | Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. ( Banerjee, ER; Chi, EY; Henderson, WR, 2005) |
| "Inflammation was observed in the intestinal mucosa of mice in the AAD group." | 5.62 | Colonic Mucosal Immune Activation in Mice with Ovalbumin-Induced Allergic Airway Disease: Association between Allergic Airway Disease and Irritable Bowel Syndrome. ( Byun, J; Choi, H; Chun, H; Jeen, Y; Keum, B; Kim, B; Kim, E; Kim, S; Kim, T; Lee, H; Lee, J; Lee, K; Yeon, J, 2021) |
| "GFR does not play a significant role in the dabigatran-induced acute kidney injury in 5/6 nephrectomy model in rats." | 4.02 | Role of glomerular filtration rate-modifying drugs in the development of anticoagulant-related nephropathy. ( Brodsky, SV; Ivanov, I; Medipally, AK; Qaisar, S; Rovin, BH; Satoskar, AA; Xiao, M, 2021) |
| "We have compared the prophylactic efficacies of quercetin and salbutamol in preventing pulmonary surfactants oxidation under hypoxia." | 4.02 | Hypoxia-mediated alterations in pulmonary surfactant protein expressions: Beneficial effects of quercetin prophylaxis. ( Kumar, B; Sagi, SSK; Tripathi, A, 2021) |
| "Male SD rats supplemented orally with quercetin (50 mg/Kg BW), and salbutamol (2 mg/Kg BW) were exposed to hypobaric hypoxia at 7620 m for 6 h." | 3.96 | Efficacy of Quercetin as a potent sensitizer of β2-AR in combating the impairment of fluid clearance in lungs of rats under hypoxia. ( Kaur, P; Kumar, B; Kumar, M; Sagi, SSK; Tripathi, A, 2020) |
| "This study characterized a novel inhaled Btk inhibitor RN983 in vitro and in ovalbumin allergic mouse models of the early (EAR) and late (LAR) asthmatic response." | 3.83 | Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma. ( Bauer, CM; Burns, L; Harris, P; Laine, D; Peng, R; Phillips, JE; Renteria, L; Stevenson, CS, 2016) |
| " albuterol, are used for quick reversal of bronchoconstriction in asthmatics." | 3.77 | Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma. ( Aimi, S; Barone, LM; Bates, JH; Irvin, CG; Lundblad, LK; Poynter, ME; Riesenfeld, EP; Rinaldi, LM; Wu, M, 2011) |
| "Effects of quercetin inhalation on immediate (IAR), late-phase (LAR) and late late-phase (LLAR) asthmatic responses by exposure to aerosolized-ovalbumin (AOA) (2w/v% in saline, inhalation for 3 min) were studied in conscious guinea-pigs sensitized with AOA." | 3.74 | Quercetin inhalation inhibits the asthmatic responses by exposure to aerosolized-ovalbumin in conscious guinea-pigs. ( Choi, HH; Kim, CJ; Lee, JY; Moon, H; Moon, HJ; Sim, SS, 2008) |
| "Clenbuterol, a compound classified as a beta2-adrenoceptor (AR) agonist, has been employed in combination with left ventricular assist devices (LVADs) to treat patients with severe heart failure." | 3.74 | Effects of clenbuterol on contractility and Ca2+ homeostasis of isolated rat ventricular myocytes. ( Arora, M; Harding, SE; Kolettis, T; Lee, J; Siedlecka, U; Soppa, GK; Stagg, MA; Terracciano, CM; Yacoub, MH, 2008) |
| "(R)- and (S)-Enantiomers of albuterol likely exert differential effects in patients with asthma." | 3.73 | Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. ( Banerjee, ER; Chi, EY; Henderson, WR, 2005) |
| " Smooth muscle relaxation was obtained by salbutamol and l-phenylephrine, whereas contraction was achieved by carbachol and 1-(3-chlorophenyl)-biguanide." | 3.72 | Effect of pharmacologically induced smooth muscle activation on permeability in murine colitis. ( Garrelds, IM; Meijssen, MA; van Meeteren, ME; Zijlstra, FJ, 2003) |
| "The following study was performed to further characterize a primate model of asthma using classes of drugs that target allergy (pyrilamine, cetirizine), are bronchodilators for the treatment of asthma (salbutamol, salmeterol) or are anti-inflammatory (dexamethasone)." | 3.69 | Characterization of a primate model of asthma using anti-allergy/anti-asthma agents. ( Andresen, CJ; Smith, WB; Turner, CR; Watson, JW, 1996) |
| " Allergic bronchial eosinophilia in guinea pigs was inhibited by orally administered dexamethasone and methylprednisolone." | 3.68 | Allergic bronchial eosinophilia: a therapeutic approach for the selection of potential bronchial anti-inflammatory drugs. ( Chand, N; De Vine, CL; Diamantis, W; Harrison, JE; Jakubicki, RG; Nolan, KW; Pillar, J; Rooney, SM; Sofia, RD, 1993) |
| "Allergic rhinitis was induced in five of the six groups with ovalbumin, and four of these five groups were treated with salbutamol, budesonide, theophylline, and montelukast." | 1.91 | Survey the effect of drug treatment on modulation of cytokines gene expression in allergic rhinitis. ( Athari, SS; Ma, Y; Tu, Y; Yang, XH, 2023) |
| "Acute colitis was established in mice with 3% dextran sulfate sodium and the mice were orally administered different salbutamol isomers." | 1.72 | Protective effects of (R)-enantiomers but not (S)-enantiomers of β2-adrenergic receptor agonists against acute colitis: The role of β2AR. ( Deng, L; Huang, J; Li, M; Lin, Y; Liu, X; Lu, Z; Tan, W; Wang, S; Zhang, R, 2022) |
| "Inflammation was observed in the intestinal mucosa of mice in the AAD group." | 1.62 | Colonic Mucosal Immune Activation in Mice with Ovalbumin-Induced Allergic Airway Disease: Association between Allergic Airway Disease and Irritable Bowel Syndrome. ( Byun, J; Choi, H; Chun, H; Jeen, Y; Keum, B; Kim, B; Kim, E; Kim, S; Kim, T; Lee, H; Lee, J; Lee, K; Yeon, J, 2021) |
| "Seizures were caused by a current delivered through ear-clip electrodes." | 1.51 | Influence of salbutamol on the anticonvulsant potency of the antiepileptic drugs in the maximal electroshock-induced seizures in mice. ( Czuczwar, SJ; Munir, D; Świąder, K; Świąder, M; Zakrocka, I; Zawadzki, A; Łuszczki, JJ, 2019) |
| "Sepsis was induced by cecal ligation and puncture surgery (CLP)." | 1.51 | Effects of salbutamol and phlorizin on acute pulmonary inflammation and disease severity in experimental sepsis. ( Aguiar, EMG; Caixeta, DC; Cardoso-Sousa, L; Costa, DPD; Cunha, TM; Espindola, FS; Faria, PR; Goulart, LR; Jardim, AC; Oliveira, TL; Sabino-Silva, R; Silva, TL; Vieira, AA; Vilela, DD, 2019) |
| "In this study, we determined whether airway remodeling and hyperresponsiveness similar to asthma are evident in this model, and whether IL-1Ra is protective." | 1.43 | Airway Remodeling and Hyperreactivity in a Model of Bronchopulmonary Dysplasia and Their Modulation by IL-1 Receptor Antagonist. ( Bourke, JE; Bui, C; Donovan, C; Lam, M; Lamanna, E; Nold, MF; Nold-Petry, CA; Royce, SG; Rudloff, I, 2016) |
| " Dose-response RL curves in affected and carrier mice indicated a lack of methacholine response." | 1.42 | Plp1 gene duplication inhibits airway responsiveness and induces lung inflammation. ( Armani, MH; Hobson, GM; Kreiger, PA; Rodriguez, E; Sakowski, L; Shaffer, TH; Waldman, SA; Zhu, Y, 2015) |
| "Mice with Pompe disease were treated with weekly rhGAA injections (20 mg/kg) and a selective β2-agonist, either albuterol (30 mg/l in drinking water) or low-dose clenbuterol (6 mg/l in drinking water)." | 1.38 | β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. ( Bali, D; Dai, J; Kishnani, PS; Koeberl, DD; Li, S; Thurberg, BL, 2012) |
| ") completely reversed the rightward shift of the formoterol dose-response curve due to beta(2)-receptor desensitisation." | 1.34 | Formoterol and beclomethasone dipropionate interact positively in antagonising bronchoconstriction and inflammation in the lung. ( Bergamaschi, M; Berti, F; Bolzoni, P; Civelli, M; Razzetti, R; Rossoni, G; Villetti, G, 2007) |
| " An increased frequency of dosing with these drugs seems preferable for cases of severe or uncontrolled asthma." | 1.34 | Optimization of dosing schedule of daily inhalant dexamethasone to minimize phase shifting of clock gene expression rhythm in the lungs of the asthma mouse model. ( Hayasaka, N; Honma, K; Honma, S; Kudo, T; Kuwaki, T; Shibata, S; Yaita, T, 2007) |
| " Seventy-two hours after the last OVA challenge, guinea pigs were anesthetized and tracheostomized, respiratory system resistance and elastance were measured and a dose-response curve to inhaled methacholine chloride was obtained." | 1.33 | Effect of salbutamol on pulmonary responsiveness in chronic pulmonary allergic inflammation in guinea pigs. ( Arantes-Costa, FM; Kasahara, DI; Lopes, FD; Martins, MA; Nunes, MP; Perini, A, 2005) |
| "Combined burn and smoke inhalation injury frequently results in acute lung injury due to a combination of airway obstruction and inflammation." | 1.33 | Continuous nebulized albuterol attenuates acute lung injury in an ovine model of combined burn and smoke inhalation. ( Bayliss, R; Cox, RA; Enkhbaatar, P; Greenhalgh, DG; Hawkins, HK; Herndon, DN; Palmieri, TL; Traber, DL; Traber, LD, 2006) |
| "We investigated this clinical sign in influenza virus-infected cotton rats (Sigmodon hispidus) and the efficacy of antiviral and anti-inflammatory therapy in reducing symptomatic disease." | 1.32 | Influenza-induced tachypnea is prevented in immune cotton rats, but cannot be treated with an anti-inflammatory steroid or a neuraminidase inhibitor. ( Eichelberger, MC; Ottolini, MG; Prince, GA, 2004) |
| " Intratracheal administration of IL-1beta or chronic administration of albuterol significantly decreased (p < 0." | 1.30 | An in vivo model of beta-adrenoceptor desensitization. ( Agrawal, DK; Chong, BT; Romero, FA; Townley, RG, 1998) |
| "Propranolol was inhaled 20 minutes after an antigen challenge in passively sensitized, anesthetized, and artificially ventilated guinea pigs." | 1.30 | Difference in bronchoprotective effects of bronchodilators on postallergic propranolol-induced bronchoconstriction. ( Fujimura, M; Ishiura, Y; Matsuda, T; Mizuhashi, K; Myou, S, 1999) |
| "Albuterol delivery was significantly (p < or = ." | 1.29 | Albuterol delivery by metered-dose inhaler in a mechanically ventilated pediatric lung model. ( Bradley, JW; Garner, SS; Habib, DM; Lesher, BA; Wiest, DB, 1996) |
| " Thus a stimulation of the mucociliary transport rate by the other major pharmacodynamic mechanisms, secretagogue activity and stimulation of pulmonary surfactant, has to be considered." | 1.27 | Pharmacodynamic mechanism and therapeutic activity of ambroxol in animal experiments. ( Disse, BG; Ziegler, HW, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (9.09) | 18.7374 |
| 1990's | 21 (21.21) | 18.2507 |
| 2000's | 31 (31.31) | 29.6817 |
| 2010's | 30 (30.30) | 24.3611 |
| 2020's | 8 (8.08) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Kim, S | 1 |
| Keum, B | 1 |
| Byun, J | 1 |
| Kim, B | 1 |
| Lee, K | 1 |
| Yeon, J | 1 |
| Lee, J | 3 |
| Choi, H | 1 |
| Kim, E | 1 |
| Jeen, Y | 1 |
| Lee, H | 1 |
| Chun, H | 1 |
| Kim, T | 1 |
| Deng, L | 1 |
| Wang, S | 1 |
| Zhang, R | 1 |
| Huang, J | 1 |
| Lin, Y | 1 |
| Liu, X | 1 |
| Lu, Z | 1 |
| Li, M | 1 |
| Tan, W | 1 |
| Ma, Y | 1 |
| Yang, XH | 1 |
| Tu, Y | 1 |
| Athari, SS | 1 |
| Cardoso-Sousa, L | 1 |
| Aguiar, EMG | 1 |
| Caixeta, DC | 1 |
| Vilela, DD | 1 |
| Costa, DPD | 1 |
| Silva, TL | 1 |
| Cunha, TM | 1 |
| Faria, PR | 1 |
| Espindola, FS | 1 |
| Jardim, AC | 1 |
| Vieira, AA | 1 |
| Oliveira, TL | 1 |
| Goulart, LR | 1 |
| Sabino-Silva, R | 1 |
| Vanhaesebrouck, AE | 2 |
| Webster, R | 1 |
| Maxwell, S | 1 |
| Rodriguez Cruz, PM | 1 |
| Cossins, J | 1 |
| Wickens, J | 1 |
| Liu, WW | 1 |
| Cetin, H | 1 |
| Cheung, J | 1 |
| Ramjattan, H | 1 |
| Palace, J | 1 |
| Beeson, D | 1 |
| Tripathi, A | 2 |
| Kumar, M | 1 |
| Kaur, P | 1 |
| Kumar, B | 2 |
| Sagi, SSK | 2 |
| Webster, RG | 1 |
| Maxwell, SE | 1 |
| Cossins, JA | 1 |
| Liu, W | 1 |
| Ueta, R | 1 |
| Yamanashi, Y | 1 |
| Beeson, DMW | 1 |
| Medipally, AK | 1 |
| Xiao, M | 1 |
| Rovin, BH | 1 |
| Satoskar, AA | 1 |
| Ivanov, I | 1 |
| Qaisar, S | 1 |
| Brodsky, SV | 1 |
| Kim, JH | 1 |
| Park, KS | 1 |
| Hong, SW | 1 |
| Gho, YS | 1 |
| Şakul, A | 1 |
| Arı, N | 1 |
| Sotnikova, R | 1 |
| Ozansoy, G | 1 |
| Karasu, Ç | 1 |
| Świąder, M | 1 |
| Zakrocka, I | 1 |
| Świąder, K | 1 |
| Zawadzki, A | 1 |
| Łuszczki, JJ | 1 |
| Czuczwar, SJ | 1 |
| Munir, D | 1 |
| McMacken, GM | 1 |
| Spendiff, S | 1 |
| Whittaker, RG | 1 |
| O'Connor, E | 1 |
| Howarth, RM | 1 |
| Boczonadi, V | 1 |
| Horvath, R | 1 |
| Slater, CR | 1 |
| Lochmüller, H | 1 |
| Akpinar, ME | 1 |
| Tekke, NS | 1 |
| Yigit, O | 1 |
| Ercan, F | 1 |
| Durna, Y | 1 |
| Kiran, D | 1 |
| Perkins, MW | 1 |
| Wong, B | 1 |
| Rodriguez, A | 1 |
| Devorak, JL | 1 |
| Alves, DA | 1 |
| Murphy, G | 1 |
| Sciuto, AM | 1 |
| Hatchwell, L | 1 |
| Girkin, J | 1 |
| Dun, MD | 1 |
| Morten, M | 1 |
| Verrills, N | 1 |
| Toop, HD | 1 |
| Morris, JC | 1 |
| Johnston, SL | 1 |
| Foster, PS | 1 |
| Collison, A | 1 |
| Mattes, J | 1 |
| Rinaldi, B | 1 |
| Capuano, A | 1 |
| Gritti, G | 1 |
| Donniacuo, M | 1 |
| Scotto Di Vettimo, A | 1 |
| Sodano, L | 1 |
| Rafaniello, C | 1 |
| Rossi, F | 1 |
| Matera, MG | 1 |
| Kanyshkova, T | 1 |
| Ehling, P | 1 |
| Cerina, M | 1 |
| Meuth, P | 1 |
| Zobeiri, M | 1 |
| Meuth, SG | 1 |
| Pape, HC | 1 |
| Budde, T | 1 |
| Ozogul, B | 1 |
| Halici, Z | 1 |
| Cadirci, E | 1 |
| Karagoz, E | 1 |
| Bayraktutan, Z | 1 |
| Yayla, M | 1 |
| Akpinar, E | 1 |
| Atamanalp, SS | 1 |
| Unal, D | 1 |
| Karamese, M | 1 |
| Trotta, T | 1 |
| Guerra, L | 1 |
| Piro, D | 1 |
| d'Apolito, M | 1 |
| Piccoli, C | 1 |
| Porro, C | 1 |
| Giardino, I | 1 |
| Lepore, S | 1 |
| Castellani, S | 1 |
| Di Gioia, S | 1 |
| Petrella, A | 1 |
| Maffione, AB | 1 |
| Casavola, V | 1 |
| Capitanio, N | 1 |
| Conese, M | 1 |
| Rodriguez, E | 2 |
| Barthold, JS | 1 |
| Kreiger, PA | 2 |
| Armani, MH | 2 |
| Wang, J | 3 |
| Michelini, KA | 1 |
| Wolfson, MR | 1 |
| Boyce, R | 1 |
| Barone, CA | 1 |
| Zhu, Y | 2 |
| Waldman, SA | 2 |
| Shaffer, TH | 2 |
| Sakowski, L | 1 |
| Hobson, GM | 1 |
| Erokhina, IL | 1 |
| Voronchikhin, PA | 1 |
| Okovityĭ, SV | 1 |
| Emel'ianova, OI | 1 |
| Wang, Y | 1 |
| Yuan, J | 1 |
| Qian, Z | 1 |
| Zhang, X | 1 |
| Chen, Y | 1 |
| Hou, X | 1 |
| Zou, J | 1 |
| Knight, JM | 1 |
| Mak, G | 1 |
| Shaw, J | 1 |
| Porter, P | 1 |
| McDermott, C | 1 |
| Roberts, L | 1 |
| You, R | 1 |
| Yuan, X | 1 |
| Millien, VO | 1 |
| Qian, Y | 1 |
| Song, LZ | 1 |
| Frazier, V | 1 |
| Kim, C | 1 |
| Kim, JJ | 1 |
| Bond, RA | 1 |
| Milner, JD | 1 |
| Zhang, Y | 1 |
| Mandal, PK | 1 |
| Luong, A | 1 |
| Kheradmand, F | 1 |
| McMurray, JS | 1 |
| Corry, DB | 1 |
| Phillips, JE | 1 |
| Renteria, L | 1 |
| Burns, L | 1 |
| Harris, P | 1 |
| Peng, R | 1 |
| Bauer, CM | 1 |
| Laine, D | 1 |
| Stevenson, CS | 1 |
| Durmuş, H | 1 |
| Ayhan, Ö | 1 |
| Çırak, S | 1 |
| Deymeer, F | 1 |
| Parman, Y | 1 |
| Franke, A | 1 |
| Eiber, N | 1 |
| Chevessier, F | 1 |
| Schlötzer-Schrehardt, U | 1 |
| Clemen, CS | 1 |
| Hashemolhosseini, S | 1 |
| Schröder, R | 1 |
| Hemmrich-Stanisak, G | 1 |
| Tolun, A | 1 |
| Serdaroğlu-Oflazer, P | 1 |
| Royce, SG | 1 |
| Nold, MF | 1 |
| Bui, C | 1 |
| Donovan, C | 1 |
| Lam, M | 1 |
| Lamanna, E | 1 |
| Rudloff, I | 1 |
| Bourke, JE | 1 |
| Nold-Petry, CA | 1 |
| Moon, H | 1 |
| Choi, HH | 1 |
| Lee, JY | 2 |
| Moon, HJ | 1 |
| Sim, SS | 1 |
| Kim, CJ | 2 |
| Siedlecka, U | 1 |
| Arora, M | 1 |
| Kolettis, T | 1 |
| Soppa, GK | 1 |
| Stagg, MA | 1 |
| Harding, SE | 1 |
| Yacoub, MH | 1 |
| Terracciano, CM | 1 |
| Kramer, EL | 1 |
| Mushaben, EM | 1 |
| Pastura, PA | 1 |
| Acciani, TH | 1 |
| Deutsch, GH | 1 |
| Khurana Hershey, GK | 1 |
| Korfhagen, TR | 1 |
| Hardie, WD | 1 |
| Whitsett, JA | 1 |
| Le Cras, TD | 1 |
| Rytting, E | 1 |
| Bur, M | 1 |
| Cartier, R | 1 |
| Bouyssou, T | 1 |
| Wang, X | 1 |
| Krüger, M | 1 |
| Lehr, CM | 1 |
| Kissel, T | 1 |
| Riesenfeld, EP | 3 |
| Sullivan, MJ | 1 |
| Thompson-Figueroa, JA | 1 |
| Haverkamp, HC | 1 |
| Lundblad, LK | 2 |
| Bates, JH | 2 |
| Irvin, CG | 3 |
| Lee, JH | 1 |
| Kim, TD | 1 |
| Rinaldi, LM | 1 |
| Poynter, ME | 1 |
| Wu, M | 1 |
| Aimi, S | 1 |
| Barone, LM | 2 |
| Toledo, AC | 1 |
| Arantes-Costa, FM | 2 |
| Macchione, M | 1 |
| Saldiva, PH | 1 |
| Negri, EM | 1 |
| Lorenzi-Filho, G | 1 |
| Martins, MA | 2 |
| Koeberl, DD | 1 |
| Li, S | 1 |
| Dai, J | 1 |
| Thurberg, BL | 1 |
| Bali, D | 1 |
| Kishnani, PS | 1 |
| Hu, Z | 1 |
| Chen, R | 1 |
| Cai, Z | 1 |
| Yu, L | 1 |
| Fei, Y | 1 |
| Weng, L | 1 |
| Ge, X | 1 |
| Zhu, T | 1 |
| Bai, C | 1 |
| Zijlstra, FJ | 1 |
| van Meeteren, ME | 1 |
| Garrelds, IM | 1 |
| Meijssen, MA | 1 |
| Devillier, P | 1 |
| Lagente, V | 1 |
| Naline, E | 1 |
| Guenon, I | 1 |
| Corbel, M | 1 |
| Boichot, E | 1 |
| Burgaud, JL | 1 |
| Del Soldato, P | 1 |
| Advenier, C | 1 |
| Eichelberger, MC | 1 |
| Prince, GA | 1 |
| Ottolini, MG | 1 |
| van Helden, HP | 1 |
| Kuijpers, WC | 1 |
| Diemel, RV | 1 |
| Nabe, T | 1 |
| Yamauchi, K | 1 |
| Shinjo, Y | 1 |
| Niwa, T | 1 |
| Imoto, K | 1 |
| Koda, A | 2 |
| Kohno, S | 1 |
| Westerhof, FJ | 1 |
| Zuidhof, AB | 1 |
| Kok, L | 1 |
| Meurs, H | 1 |
| Zaagsma, J | 1 |
| Kasahara, DI | 1 |
| Perini, A | 1 |
| Lopes, FD | 1 |
| Nunes, MP | 1 |
| Auais, A | 1 |
| Wedde-Beer, K | 1 |
| Piedimonte, G | 1 |
| Henderson, WR | 1 |
| Banerjee, ER | 1 |
| Chi, EY | 1 |
| Bonnet, N | 2 |
| Brunet-Imbault, B | 1 |
| Arlettaz, A | 1 |
| Horcajada, MN | 1 |
| Collomp, K | 1 |
| Benhamou, CL | 2 |
| Courteix, D | 2 |
| Tanaka, S | 1 |
| Yamagishi, R | 1 |
| Tsutsui, M | 1 |
| Kishida, T | 1 |
| Murakami, M | 1 |
| Kuroda, J | 1 |
| Yoshida, T | 1 |
| Palmieri, TL | 1 |
| Enkhbaatar, P | 1 |
| Bayliss, R | 1 |
| Traber, LD | 1 |
| Cox, RA | 1 |
| Hawkins, HK | 1 |
| Herndon, DN | 1 |
| Greenhalgh, DG | 1 |
| Traber, DL | 1 |
| Wiener-Kronish, JP | 1 |
| Matthay, MA | 2 |
| Milgrom, H | 1 |
| Ameredes, BT | 1 |
| Calhoun, WJ | 1 |
| Razzetti, R | 1 |
| Bergamaschi, M | 1 |
| Villetti, G | 1 |
| Bolzoni, P | 1 |
| Civelli, M | 1 |
| Berti, F | 1 |
| Rossoni, G | 1 |
| Hayasaka, N | 1 |
| Yaita, T | 1 |
| Kuwaki, T | 1 |
| Honma, S | 1 |
| Honma, K | 1 |
| Kudo, T | 1 |
| Shibata, S | 1 |
| Laroche, N | 1 |
| Beaupied, H | 1 |
| Vico, L | 1 |
| Dolleans, E | 1 |
| Kneilling, M | 1 |
| Hültner, L | 1 |
| Pichler, BJ | 1 |
| Mailhammer, R | 1 |
| Morawietz, L | 1 |
| Solomon, S | 1 |
| Eichner, M | 1 |
| Sabatino, J | 1 |
| Biedermann, T | 1 |
| Krenn, V | 1 |
| Weber, WA | 1 |
| Illges, H | 1 |
| Haubner, R | 1 |
| Röcken, M | 1 |
| Kelly, HW | 1 |
| Mitchell, H | 1 |
| Noble, P | 1 |
| McFawn, P | 1 |
| Ferrada, MA | 1 |
| Gordon, EL | 1 |
| Jen, KY | 1 |
| He, HZ | 1 |
| Lu, X | 1 |
| Amirifeli, S | 1 |
| Perkins, DL | 1 |
| Finn, PW | 1 |
| Liu, H | 1 |
| Zhou, LF | 1 |
| Zhang, Q | 1 |
| Qian, FH | 1 |
| Yin, KS | 1 |
| Huang, M | 1 |
| Zhang, XL | 1 |
| Vardi, Y | 1 |
| Regev, I | 1 |
| Rosenbaum, M | 1 |
| Flechter, S | 1 |
| Arai, Y | 1 |
| Nitta, K | 1 |
| Shida, T | 1 |
| Shioda, H | 1 |
| Hahn, DW | 1 |
| McGuire, JL | 1 |
| Vanderhoof, M | 1 |
| Ericson, E | 1 |
| Pasquale, SA | 1 |
| Chand, N | 2 |
| Achterrath-Tuckermann, U | 1 |
| Szelenyi, I | 1 |
| Sofia, RD | 2 |
| Gardiner, SM | 1 |
| March, JE | 1 |
| Kemp, PA | 1 |
| Bennett, T | 1 |
| O'Donnell, M | 1 |
| Garippa, RJ | 1 |
| Rinaldi, N | 1 |
| Selig, WM | 1 |
| Tocker, JE | 1 |
| Tannu, SA | 1 |
| Wasserman, MA | 1 |
| Welton, A | 1 |
| Bolin, DR | 1 |
| Harrison, JE | 1 |
| Rooney, SM | 1 |
| Nolan, KW | 1 |
| De Vine, CL | 1 |
| Jakubicki, RG | 1 |
| Pillar, J | 1 |
| Diamantis, W | 1 |
| Imagawa, J | 1 |
| Kamei, K | 1 |
| Yoshida, S | 1 |
| Sugo, I | 1 |
| Koga, T | 1 |
| Nabata, H | 1 |
| Church, MK | 1 |
| Hutson, PA | 1 |
| Holgate, ST | 1 |
| Garner, SS | 1 |
| Wiest, DB | 1 |
| Bradley, JW | 1 |
| Lesher, BA | 1 |
| Habib, DM | 1 |
| Turner, CR | 1 |
| Andresen, CJ | 1 |
| Smith, WB | 1 |
| Watson, JW | 1 |
| Saleh, TS | 1 |
| Calixto, JB | 1 |
| Medeiros, YS | 1 |
| Kalish, R | 1 |
| Wood, JA | 1 |
| Wille, JJ | 1 |
| Kydonieus, A | 1 |
| Inoue, H | 1 |
| Aizawa, H | 1 |
| Matsumoto, K | 1 |
| Shigyo, M | 1 |
| Takata, S | 1 |
| Hara, M | 1 |
| Hara, N | 1 |
| Fujimura, M | 2 |
| Amemiya, M | 1 |
| Myou, S | 2 |
| Mizuguchi, M | 1 |
| Matsuda, T | 2 |
| Chong, BT | 1 |
| Agrawal, DK | 1 |
| Romero, FA | 1 |
| Townley, RG | 1 |
| Kimoto, A | 1 |
| Saitou, M | 1 |
| Hirano, Y | 1 |
| Iwai, T | 1 |
| Tomioka, K | 1 |
| Miyata, K | 1 |
| Yamada, T | 1 |
| Mizuhashi, K | 1 |
| Ishiura, Y | 1 |
| Berthiaume, Y | 1 |
| Folkesson, HG | 1 |
| Mohammed, SP | 1 |
| Taylor, CV | 1 |
| Weyman-Jones, CB | 1 |
| Mather, ME | 1 |
| Vendy, K | 1 |
| Dougall, IG | 1 |
| Young, A | 1 |
| Malfait, AM | 1 |
| Williams, RO | 1 |
| Malik, AS | 1 |
| Maini, RN | 1 |
| Feldmann, M | 1 |
| Fozard, JR | 1 |
| Buescher, H | 1 |
| McDonald, DM | 1 |
| Weissberg, RM | 1 |
| Harken, AH | 1 |
| Pringle, JM | 1 |
| Badoux, S | 1 |
| Norwood, CW | 1 |
| Poole, J | 1 |
| Moody, D | 1 |
| Yamada, N | 1 |
| Kadowaki, S | 1 |
| Umezu, K | 1 |
| Smith, TL | 1 |
| Koman, LA | 1 |
| Tarayre, JP | 2 |
| Aliaga, M | 2 |
| Barbara, M | 2 |
| Tisseyre, N | 2 |
| Vieu, S | 2 |
| Tisne-Versailles, J | 2 |
| Suda, H | 1 |
| Nagai, H | 1 |
| Iwama, T | 1 |
| Overstreet, DH | 1 |
| Double, K | 1 |
| Schiller, GD | 1 |
| Wamil, A | 1 |
| Kleinrok, Z | 1 |
| Disse, BG | 1 |
| Ziegler, HW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Clinical Investigation of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease, Whether or Not Receiving Enzyme Replacement Therapy[NCT01859624] | Phase 1 | 8 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy[NCT01942590] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Phase 1/2 Double-Blind Study of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy[NCT01885936] | Phase 1/Phase 2 | 16 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assess exercise tolerance in study patients; test administered by physical therapist. Subjects were asked to walk for 6 minutes, unassisted. The distance walked was recorded in meters. (NCT01942590)
Timeframe: Baseline, week 18
| Intervention | meters (Mean) |
|---|---|
| Clenbuterol | 18.09 |
| Placebo Comparator | 6.878 |
Assess exercise tolerance in study patients; test administered by physical therapist. Subjects were asked to walk for 6 minutes, unassisted. The distance walked was recorded in meters. (NCT01942590)
Timeframe: Baseline, week 52
| Intervention | meters (Mean) |
|---|---|
| Clenbuterol | 16.42 |
| Placebo Comparator | -18.13 |
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. (NCT01942590)
Timeframe: Baseline, Week 18
| Intervention | change in FVC measured as % expected (Mean) |
|---|---|
| Clenbuterol | 1.575 |
| Placebo Comparator | 2.825 |
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. (NCT01942590)
Timeframe: Baseline, Week 52
| Intervention | change in FVC measured as % expected (Mean) |
|---|---|
| Clenbuterol | -5.738 |
| Placebo Comparator | 7.775 |
(NCT01942590)
Timeframe: Baseline, Week 52
| Intervention | mmol/mol CN (Mean) |
|---|---|
| Clenbuterol | -1.1 |
| Placebo Comparator | -1.667 |
The Glc4 biomarker is measured in urine and correlates with muscle glycogen content. It is a noninvasive measurement that serves as a biomarker for Pompe disease. (NCT01942590)
Timeframe: Baseline, Week 18
| Intervention | mmol/mol CN (Mean) |
|---|---|
| Clenbuterol | -1.733 |
| Placebo Comparator | 0.0667 |
Liver toxicity, as defined by a >3x increase in AST or ALT from the respective baseline values and/or an increase in direct, indirect or total bilirubin of >3x the upper limit of normal (NCT01942590)
Timeframe: Any point up to week 52
| Intervention | participants (Number) |
|---|---|
| Clenbuterol | 0 |
| Placebo Comparator | 0 |
Worsening muscle involvement, as defined by >3x increase in CK from baseline that is >2x the upper limit of normal (NCT01942590)
Timeframe: Any point up to week 52
| Intervention | participants (Number) |
|---|---|
| Clenbuterol | 1 |
| Placebo Comparator | 0 |
The GSGC is a criterion referenced assessment designed to measure functional status and change in gross motor function over time and, in particular, to measure clinically relevant change. Consists of 4 components: Gait, Climbing Stairs, Gower's Manuever, Arising From a Chair. Lowest score 4 = normal muscle function, highest score 27 = unable to perform motor function tests. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 17 | 15.14 | 13.8 |
| Placebo Comparator | 7.5 | 6.5 | 6.5 |
The Late-Life Function & Disability Instrument (Late-Life FDI) is an evaluative outcome instrument for community-dwelling older adults. Highest score 240 = normal function and no disability, lowest score 0 = low levels of frequency of participating in life tasks. (NCT01942590)
Timeframe: Baseline, Week 18, Week 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 103.75 | 106.7 | 112.5 |
MEP reflects the strength of the abdominal muscles and other expiratory muscles. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | percentage of MEP (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 40.4 | 40 | 53.9 |
| Placebo Comparator | 62.8 | 83.3 | 49.2 |
MIP is a measurement of inspiratory muscle weakness, including weakness of the diaphragm. MIP is decreased in Pompe disease and reflects weakness of respiratory muscles. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | percentage of MIP (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 56.3 | 47.4 | 68.5 |
| Placebo Comparator | 96.8 | 83.8 | 104.6 |
The QMFT is a criterion referenced assessment designed to measure functional status and change in gross motor function over time and, in particular, to measure clinically relevant change. Consists of 16 motor function tests. Lowest score 0 = unable to perform motor function tests, highest score 64 = normal muscle function. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 35 | 40.6 | 46.5 |
| Placebo Comparator | 53.75 | 54.75 | 56.25 |
All participants who experienced adverse events. (NCT01885936)
Timeframe: 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Albuterol | 5 |
| Placebo Comparator | 5 |
The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. Assessed by physical therapist. (NCT01885936)
Timeframe: Baseline, Week 6, and Week 52
| Intervention | meters (Mean) | |
|---|---|---|
| Change at 6 Weeks | Change at 52 Weeks | |
| Albuterol | 24.0 | 43.6 |
| Placebo Comparator | 32.0 | 13.6 |
FVC (forced vital capacity) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. (NCT01885936)
Timeframe: Baseline, Week 30, and Week 52
| Intervention | Percent of predicted FVC (Mean) | |
|---|---|---|
| Change at 30 Weeks | Change at 52 Weeks | |
| Albuterol | -0.2 | -1.3 |
| Placebo Comparator | 0.4 | 3.0 |
2 reviews available for albuterol and Disease Models, Animal
| Article | Year |
|---|---|
[Physiopathology of COPD: choosing the right therapeutic targets].
Topics: Adrenal Cortex Hormones; Aged; Albuterol; Animals; Bacterial Infections; Bronchodilator Agents; Carb | 2003 |
Levalbuterol for asthma: a better treatment?
Topics: Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Bronchodilator Agents; Clinical Trials as Top | 2007 |
97 other studies available for albuterol and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Colonic Mucosal Immune Activation in Mice with Ovalbumin-Induced Allergic Airway Disease: Association between Allergic Airway Disease and Irritable Bowel Syndrome.
Topics: Administration, Intranasal; Albuterol; Animals; Disease Models, Animal; Inflammation; Intestinal Muc | 2021 |
Protective effects of (R)-enantiomers but not (S)-enantiomers of β2-adrenergic receptor agonists against acute colitis: The role of β2AR.
Topics: Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Colitis; Colitis, Ulce | 2022 |
Survey the effect of drug treatment on modulation of cytokines gene expression in allergic rhinitis.
Topics: Albuterol; Animals; Budesonide; Cytokines; Disease Models, Animal; Gene Expression; Male; Mice; Mice | 2023 |
Effects of salbutamol and phlorizin on acute pulmonary inflammation and disease severity in experimental sepsis.
Topics: Acute Lung Injury; Albuterol; Alveolar Epithelial Cells; Animals; Bronchoalveolar Lavage Fluid; Cyto | 2019 |
β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.
Topics: Action Potentials; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Cholinesterase Inhibitor | 2019 |
Efficacy of Quercetin as a potent sensitizer of β2-AR in combating the impairment of fluid clearance in lungs of rats under hypoxia.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Antioxidants; Body Fluids; Cyclic AMP-Depen | 2020 |
Effect of salbutamol on neuromuscular junction function and structure in a mouse model of DOK7 congenital myasthenia.
Topics: Albuterol; Animals; Disease Models, Animal; Female; Humans; Mice; Muscle Proteins; Myasthenic Syndro | 2020 |
Role of glomerular filtration rate-modifying drugs in the development of anticoagulant-related nephropathy.
Topics: Acute Kidney Injury; Albuterol; Animals; Antihypertensive Agents; Antithrombins; Bronchodilator Agen | 2021 |
Hypoxia-mediated alterations in pulmonary surfactant protein expressions: Beneficial effects of quercetin prophylaxis.
Topics: Albuterol; Animals; Antioxidants; Bronchodilator Agents; Disease Models, Animal; Hypoxia; Male; Oxid | 2021 |
Drug Repositioning to Alleviate Systemic Inflammatory Response Syndrome Caused by Gram-Negative Bacterial Outer Membrane Vesicles.
Topics: Albuterol; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Repositioning; Ex | 2018 |
A pyridoindole antioxidant SMe1EC2 regulates contractility, relaxation ability, cation channel activity, and protein-carbonyl modifications in the aorta of young and old rats with or without diabetes mellitus.
Topics: Acetylcholine; Aging; Albuterol; Animals; Antioxidants; Aorta, Thoracic; Diabetes Mellitus, Experime | 2018 |
Influence of salbutamol on the anticonvulsant potency of the antiepileptic drugs in the maximal electroshock-induced seizures in mice.
Topics: Albuterol; Animals; Anticonvulsants; Avoidance Learning; Brain; Disease Models, Animal; Dose-Respons | 2019 |
Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome.
Topics: Acetylcholinesterase; Adrenergic beta-Agonists; Agrin; Albuterol; Animals; Collagen; Disease Models, | 2019 |
Histological effects of inhaled corticosteroids and ß2-agonists on laryngeal mucosa in an allergic rat model.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Androstadienes; Animals; Disease Mod | 2013 |
Inhalation toxicity of soman vapor in non-anesthetized rats: a preliminary assessment of inhaled bronchodilator or steroid therapy.
Topics: Acetylcholinesterase; Acute Lung Injury; Administration, Inhalation; Adrenal Cortex Hormones; Albute | 2013 |
Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease by modulating protein phosphatase 2A.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Antigens, Dermatophagoides; Chemotaxis; Dis | 2014 |
Effects of chronic administration of β-blockers on airway responsiveness in a murine model of heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Bro | 2014 |
Regionally specific expression of high-voltage-activated calcium channels in thalamic nuclei of epileptic and non-epileptic rats.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Animals, Newborn; Biophysical Phenomena; Ca | 2014 |
Comparative study on effects of nebulized and oral salbutamol on a cecal ligation and puncture-induced sepsis model in rats.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-2 Receptor Agonists; Albuterol; An | 2015 |
Stimulation of β2-adrenergic receptor increases CFTR function and decreases ATP levels in murine hematopoietic stem/progenitor cells.
Topics: Adenosine Triphosphate; Albuterol; Analysis of Variance; Animals; Biomarkers; Cells, Cultured; Chlor | 2015 |
The orl rat is more responsive to methacholine challenge than wild type.
Topics: Administration, Inhalation; Albuterol; Animals; Anti-Asthmatic Agents; Asthma; Bronchoconstrictor Ag | 2014 |
Plp1 gene duplication inhibits airway responsiveness and induces lung inflammation.
Topics: Albuterol; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gene Duplicati | 2015 |
[Reaction of population of pulmonary mast cells in rat bronchial asthma under the effect of β-adrenoreceptor antagonists].
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Alcian Blue; Animals; Anti-Asthmat | 2013 |
β2 adrenergic receptor activation governs cardiac repolarization and arrhythmogenesis in a guinea pig model of heart failure.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Amrinone; Animals; Arrhythmias, Ca | 2015 |
Long-Acting Beta Agonists Enhance Allergic Airway Disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Anti-Asthmatic Agents; Arrestins; Aspergill | 2015 |
Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Agammaglobulinaemia Tyrosine Kinase | 2016 |
Neuromuscular endplate pathology in recessive desminopathies: Lessons from man and mice.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Cardiomyopathies; Child; Consan | 2016 |
Airway Remodeling and Hyperreactivity in a Model of Bronchopulmonary Dysplasia and Their Modulation by IL-1 Receptor Antagonist.
Topics: Airway Remodeling; Albuterol; Animals; Bronchial Hyperreactivity; Bronchopulmonary Dysplasia; Diseas | 2016 |
Quercetin inhalation inhibits the asthmatic responses by exposure to aerosolized-ovalbumin in conscious guinea-pigs.
Topics: Administration, Inhalation; Administration, Oral; Aerosols; Airway Resistance; Albuterol; Animals; A | 2008 |
Effects of clenbuterol on contractility and Ca2+ homeostasis of isolated rat ventricular myocytes.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Animals; Calcium Channels, L-Type; | 2008 |
Early growth response-1 suppresses epidermal growth factor receptor-mediated airway hyperresponsiveness and lung remodeling in mice.
Topics: Airway Resistance; Albuterol; Animals; Bronchial Hyperreactivity; Cells, Cultured; Disease Models, A | 2009 |
In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles.
Topics: Albuterol; Animals; Biocompatible Materials; Bronchial Spasm; Bronchodilator Agents; Disease Models, | 2010 |
Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Animals; Asthma; Disease Models, Animal; Drug | 2010 |
Antiasthmatic action of dibenzylbutyrolactone lignans from fruits of Forsythia viridissima on asthmatic responses to ovalbumin challenge in conscious guinea-pigs.
Topics: 4-Butyrolactone; Airway Resistance; Albuterol; Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveol | 2011 |
Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Analysis of Variance; An | 2011 |
Salbutamol improves markers of epithelial function in mice with chronic allergic pulmonary inflammation.
Topics: Airway Remodeling; Albuterol; Animals; Bronchoalveolar Lavage Fluid; Bronchodilator Agents; Chronic | 2011 |
Asthma treatment through the beta receptor: lessons from animal models.
Topics: Adrenergic beta-Antagonists; Albuterol; Animals; Asthma; Disease Models, Animal; Stereoisomerism | 2011 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
Salmeterol attenuates the inflammatory response in asthma and decreases the pro-inflammatory cytokine secretion of dendritic cells.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Cells, Cultured; Cytokines; Dendrit | 2012 |
Effect of pharmacologically induced smooth muscle activation on permeability in murine colitis.
Topics: Albuterol; Animals; Biguanides; Carbachol; Colitis; Dextran Sulfate; Disease Models, Animal; Female; | 2003 |
A nitric oxide-releasing salbutamol elicits potent relaxant and anti-inflammatory activities.
Topics: Albuterol; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage; Bronchodilator Agents; Cell Mo | 2004 |
Influenza-induced tachypnea is prevented in immune cotton rats, but cannot be treated with an anti-inflammatory steroid or a neuraminidase inhibitor.
Topics: Albuterol; Animals; Anti-Inflammatory Agents; Antiviral Agents; Bronchodilator Agents; Disease Model | 2004 |
Asthmalike symptoms following intratracheal exposure of Guinea pigs to sulfur mustard aerosol: therapeutic efficacy of exogenous lung surfactant curosurf and salbutamol.
Topics: Aerosols; Albuterol; Animals; Asthma; Biological Products; Bronchoalveolar Lavage Fluid; Bronchodila | 2004 |
Delayed-type asthmatic response induced by repeated intratracheal exposure to toluene-2,4-diisocyanate in guinea pigs.
Topics: Airway Resistance; Albumins; Albuterol; Allergens; Animals; Asthma; Chromones; Dexamethasone; Diseas | 2005 |
Effects of salbutamol and enantiomers on allergen-induced asthmatic reactions and airway hyperreactivity.
Topics: Albuterol; Allergens; Animals; Asthma; Bronchial Hyperreactivity; Disease Models, Animal; Guinea Pig | 2005 |
Effect of salbutamol on pulmonary responsiveness in chronic pulmonary allergic inflammation in guinea pigs.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Chronic Disease; Disease Models, Animal; Dose- | 2005 |
Anti-inflammatory effect of albuterol enantiomers during respiratory syncytial virus infection in rats.
Topics: Administration, Inhalation; Aerosols; Albumins; Albuterol; Animals; Anti-Inflammatory Agents; Diseas | 2005 |
Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Apoptosis; Asthma; Bronchial Hyperreactivity; Disease | 2005 |
Alteration of trabecular bone under chronic beta2 agonists treatment.
Topics: Adipose Tissue; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Animals; B | 2005 |
Tissue- and dose-dependent alteration of stress-inducible proteins by beta2-adrenoceptor agonist, salbutamol, in rats.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-2 Receptor Antagonists; Albuterol; Animals; Cyt | 2005 |
Continuous nebulized albuterol attenuates acute lung injury in an ovine model of combined burn and smoke inhalation.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Bronchoconstriction; Disea | 2006 |
Beta-2-agonist treatment as a potential therapy for acute inhalational lung injury.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Disease Models, Animal; In | 2006 |
Levosalbutamol in the treatment of asthma.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Bronchial Provocation T | 2006 |
(R)-albuterol for asthma: pro [a.k.a. (S)-albuterol for asthma: con].
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Cost of Illness; Disease Models, Animal; Disea | 2006 |
Formoterol and beclomethasone dipropionate interact positively in antagonising bronchoconstriction and inflammation in the lung.
Topics: Acetylcholine; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Animals; An | 2007 |
Optimization of dosing schedule of daily inhalant dexamethasone to minimize phase shifting of clock gene expression rhythm in the lungs of the asthma mouse model.
Topics: Acetylcholine; Administration, Inhalation; Albuterol; Animals; Anti-Inflammatory Agents; Asthma; Cel | 2007 |
Doping dose of salbutamol and exercise training: impact on the skeleton of ovariectomized rats.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Biomechanical Phenomena; Body Mass Index; Bone and Bon | 2007 |
Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice.
Topics: Albuterol; Animals; Antibodies, Anti-Idiotypic; Arthritis, Rheumatoid; Cromolyn Sodium; Cyclic AMP; | 2007 |
Commentary on "The role of the large airways on smooth muscle contraction in asthma".
Topics: Albuterol; Animals; Asthma; Bronchi; Bronchodilator Agents; Disease Models, Animal; Humans; Lung Vol | 2007 |
(R)-albuterol decreases immune responses: role of activated T cells.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Cell Line; Cells, Cultured; Disease Models, Animal; Eo | 2008 |
Increased RhoGDI2 and peroxiredoxin 5 levels in asthmatic murine model of beta2-adrenoceptor desensitization: a proteomics approach.
Topics: Albuterol; Animals; Asthma; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Female; G | 2008 |
The behavioral effect of salbutamol (a beta-adrenergic receptor stimulant) on reserpine- and propranolol-treated rats.
Topics: Albuterol; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Humans; Propranolol; | 1983 |
Anti-asthmatic effects and drug tolerance of selective beta 2-adrenergic stimulants in guinea-pigs.
Topics: Albuterol; Animals; Asthma; Disease Models, Animal; Drug Tolerance; Ethanolamines; Fenoterol; Guinea | 1983 |
Evaluation of drugs for arrest of premature labor in a new animal model.
Topics: Albuterol; Animals; Calcium Channel Blockers; Disease Models, Animal; Dose-Response Relationship, Dr | 1984 |
Synergistic protective effects with azelastine and salbutamol in a guinea pig asthma model.
Topics: Administration, Oral; Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Bronchodilator Agents; | 1995 |
Resting cardiovascular status and vasodilator function in a vasopressin-deficient, hypertensive strain of rat.
Topics: Acetylcholine; Albuterol; Animals; Blood Pressure; Bradykinin; Disease Models, Animal; Hemodynamics; | 1994 |
Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis.
Topics: Albuterol; Anaphylaxis; Animals; Antigens; Asthma; Bronchoalveolar Lavage Fluid; Bronchodilator Agen | 1994 |
Allergic bronchial eosinophilia: a therapeutic approach for the selection of potential bronchial anti-inflammatory drugs.
Topics: Albuterol; Allergens; Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; Bronchoa | 1993 |
In vivo bronchodilator action of a novel K+ channel opener, KC 399, in the guinea pig.
Topics: Administration, Inhalation; Albuterol; Anesthesia; Animals; Antigens; Asthma; Benzopyrans; Bronchoco | 1994 |
Nedocromil sodium blocks the early and late phases of allergen challenge in a guinea pig model of asthma.
Topics: Aerosols; Albuterol; Allergens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchoalv | 1993 |
Albuterol delivery by metered-dose inhaler in a mechanically ventilated pediatric lung model.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Disease Models, Animal; Drug Delivery Systems; Drug | 1996 |
Characterization of a primate model of asthma using anti-allergy/anti-asthma agents.
Topics: Albuterol; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents; Antigens; Asthma; Bronchoconstri | 1996 |
Anti-inflammatory effects of theophylline, cromolyn and salbutamol in a murine model of pleurisy.
Topics: Albuterol; Animals; Cromolyn Sodium; Disease Models, Animal; Dose-Response Relationship, Drug; Femal | 1996 |
Sensitization of mice to topically applied drugs: albuterol, chlorpheniramine, clonidine and nadolol.
Topics: Administration, Cutaneous; Albuterol; Animals; Anti-Asthmatic Agents; Antihypertensive Agents; Biolo | 1996 |
Effect of beta 2-agonists on histamine-induced airway microvascular leakage in ozone-exposed guinea pigs.
Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Animals; Blood-Air Barrier; Bronchial Hyperr | 1997 |
A guinea-pig model of ultrasonically nebulized distilled water-induced bronchoconstriction.
Topics: Administration, Inhalation; Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Bronchial Provoca | 1997 |
An in vivo model of beta-adrenoceptor desensitization.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchoconstrictor | 1998 |
A new, simple method for measuring mucociliary clearance in guinea-pigs.
Topics: Adrenergic beta-Antagonists; Air Pollutants; Albuterol; Animals; Disease Models, Animal; Guinea Pigs | 1999 |
Difference in bronchoprotective effects of bronchodilators on postallergic propranolol-induced bronchoconstriction.
Topics: Airway Resistance; Albuterol; Aminophylline; Animals; Atropine; Bronchi; Bronchial Hyperreactivity; | 1999 |
Indomethacin does not influence alveolar liquid clearance in anesthetized sheep or rats.
Topics: Adrenergic beta-Agonists; Albuterol; Anesthesia; Animals; Cyclic AMP; Cyclooxygenase Inhibitors; Din | 1999 |
Duration of action of inhaled vs. Intravenous beta(2)-adrenoceptor agonists in an anaesthetized guinea-pig model.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Bronchodilator Agents; Dis | 2000 |
Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, M | 2001 |
Comparison of the anti-bronchoconstrictor activities of inhaled formoterol, its (R,R)- and (S,S)-enantiomers and salmeterol in the rhesus monkey.
Topics: Administration, Inhalation; Airway Resistance; Albuterol; Animals; Bronchial Spasm; Bronchoconstrict | 2001 |
Angiogenesis and remodeling of airway vasculature in chronic inflammation.
Topics: Adrenergic beta-Antagonists; Adult; Albuterol; Angiopoietin-1; Animals; Asthma; Bronchitis; Bronchod | 2001 |
Conscious primate model for evaluating antiallergic drugs.
Topics: Albuterol; Animals; Ascaris; Cromolyn Sodium; Disease Models, Animal; Haplorhini; Histamine Release; | 1979 |
Autonomic control of pulmonary trapped gas volume in subhuman primates.
Topics: Albuterol; Animals; Atropine; Autonomic Nervous System; Bronchi; Disease Models, Animal; Functional | 1978 |
Treatment of experiment delayed cerebral arterial spasm with a beta2-adrenergic stimulator and a phosphodiesterase inhibitor.
Topics: Albuterol; Aminophylline; Animals; Disease Models, Animal; Drug Therapy, Combination; Haplorhini; Is | 1976 |
Development of an animal model of late asthmatic response in guinea pigs and effects of anti-asthmatic drugs.
Topics: Albuterol; Allergens; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cromolyn Sodium; Cytodiagnosis; | 1992 |
Development of a new rabbit ear model for the longitudinal study of digital pathophysiology.
Topics: Albuterol; Animals; Aorta, Abdominal; Blood Pressure; Catheterization, Peripheral; Clonidine; Diseas | 1992 |
Model of bronchial allergic inflammation in the brown Norway rat. Pharmacological modulation.
Topics: Albuterol; Animals; Bronchitis; Dexamethasone; Disease Models, Animal; Ketotifen; Male; Ovalbumin; R | 1992 |
Effects of NZ-107 on bronchoconstriction in guinea pigs.
Topics: Albuterol; Animals; Asthma; Bronchoconstriction; Cromolyn Sodium; Disease Models, Animal; Guinea Pig | 1992 |
Pharmacological modulation of a model of bronchial inflammation after aerosol-induced active anaphylactic shock in conscious guinea pigs.
Topics: Albuterol; Anaphylaxis; Animals; Asthma; Bronchitis; Bronchoalveolar Lavage Fluid; Cromolyn Sodium; | 1991 |
Antidepressant effects of rolipram in a genetic animal model of depression: cholinergic supersensitivity and weight gain.
Topics: Albuterol; Animals; Antidepressive Agents; Avoidance Learning; Body Temperature; Brain; Depressive D | 1989 |
Role of noradrenergic system in limbic seizures induced by pilocarpine. I. Importance of beta-adrenergic receptor.
Topics: Albuterol; Animals; Disease Models, Animal; Lidocaine; Limbic System; Male; Pilocarpine; Propranolol | 1988 |
Pharmacodynamic mechanism and therapeutic activity of ambroxol in animal experiments.
Topics: Albuterol; Ambroxol; Animals; Bromhexine; Cilia; Disease Models, Animal; Guinea Pigs; In Vitro Techn | 1987 |